Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Retained Earnings (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Retained Earnings data on record, last reported at -$2.5 billion in Q1 2026.

  • On a quarterly basis, Retained Earnings fell 61.9% to -$2.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.5 billion, a 61.9% decrease, with the full-year FY2025 number at -$2.2 billion, down 55.22% from a year prior.
  • Retained Earnings reached -$2.5 billion in Q1 2026 per PCVX's latest filing, down from -$2.2 billion in the prior quarter.
  • Over the last five years, Retained Earnings for PCVX hit a ceiling of $856000.0 in Q3 2025 and a floor of -$2.5 billion in Q1 2026.
  • A 5-year average of -$826.5 million and a median of -$650.9 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 4826887.5% in 2022, then soared 515.83% in 2025.
  • Tracing PCVX's Retained Earnings over 5 years: stood at -$522.1 million in 2022, then soared by 100.03% to $179000.0 in 2023, then crashed by 775697.21% to -$1.4 billion in 2024, then tumbled by 55.22% to -$2.2 billion in 2025, then dropped by 14.88% to -$2.5 billion in 2026.
  • Business Quant data shows Retained Earnings for PCVX at -$2.5 billion in Q1 2026, -$2.2 billion in Q4 2025, and $856000.0 in Q3 2025.